CEMP1 and infection: Recombinant Cp23 has been used to demonstrate humoral and cellular immune responses to C. parvum in human, cattle, and mouse infections, whereas recombinant Cp23 and DNA-based vaccines have been used to immunize mice and to elicit an innate immune response from mouse and human dendritic cells in vitro [29, 38–45].